Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder

Brain, Behavior, and Immunity

Volumn 56, Issue , 2016, Pages 281-288

  Goldsmith, David R ^a   Haroon, Ebrahim ^a   Woolwine, Bobbi J ^a   Jung, Moon Y ^a   Wommack, Evanthia C ^a   Harvey, Philip D ^c,d   Treadway, Michael T ^b   Felger, Jennifer C ^a,b   Miller, Andrew H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemokines; Cognition; Cytokines; Depression; Inflammation; Psychomotor speed

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; CCL2 PROTEIN, HUMAN; CYTOKINE; IL6 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BASAL GANGLION; BODY MASS; BRAIN CORTEX; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HUMAN; INFLAMMATORY DISEASE; LATENT PERIOD; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PERFORMANCE; MENTAL TEST; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; RACE; SEX; TASK PERFORMANCE; BLOOD; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADULT; CHEMOKINE CCL2; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; YOUNG ADULT;

EID: 84962385407     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.03.025     Document Type: Article

References (74)

1. Aas M., Dazzan P., Mondelli V., Melle I., Murray R.M., Pariante C.M. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front. Psychiatry 2014, 4:182.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Washington DC 2013.
3. Aparicio P., Diedrichsen J., Ivry R.B. Effects of focal basal ganglia lesions on timing and force control. Brain Cogn. 2005, 58:62-74.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 1995, 57:289-300.
5. Bermel R.A., Bakshi R., Tjoa C., Puli S.R., Jacobs L. Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. Arch. Neurol. 2002, 59:275-280.
6. Bersano A., Aghemo A., Rumi M.G., Ballabio E., Candelise L., Colombo M. Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur. J. Intern. Med. 2008, 19:370-371.
7. Bluthe R.M., Michaud B., Poli V., Dantzer R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol. Behav. 2000, 70:367-373.
8. Bortolato B., Carvalho A.F., Soczynska J.K., Perini G.I., McIntyre R.S. The involvement of TNF-alpha in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments. Curr. Neuropharmacol. 2015, 13:558-576.
9. Bruder G.E., Alvarenga J.E., Alschuler D., Abraham K., Keilp J.G., Hellerstein D.J., Stewart J.W., McGrath P.J. Neurocognitive predictors of antidepressant clinical response. J. Affect. Disord. 2014, 166:108-114.
10. Brydon L., Harrison N.A., Walker C., Steptoe A., Critchley H.D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry 2008, 63:1022-1029.
11. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
12. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007, 32:2384-2392.
13. Capuron L., Pagnoni G., Drake D.F., Woolwine B.J., Spivey J.R., Crowe R.J., Votaw J.R., Goodman M.M., Miller A.H. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch. Gen. Psychiatry 2012, 69:1044-1053.
14. Carvalho A.F., Miskowiak K.K., Hyphantis T.N., Kohler C.A., Alves G.S., Bortolato B., Sales P.Mg., Machado-Vieira R., Berk M., McIntyre R.S. Cognitive dysfunction in depression - pathophysiology and novel targets. CNS Neurol. Disord.: Drug Targets 2014, 13:1819-1835.
15. Chang H.H., Lee I.H., Gean P.W., Lee S.Y., Chi M.H., Yang Y.K., Lu R.B., Chen P.S. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav. Immun. 2012, 26:90-95.
16. Cohen R.A., de la Monte S., Gongvatana A., Ombao H., Gonzalez B., Devlin K.N., Navia B., Tashima K.T. Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning. J. Neuroimmunol. 2011, 233:204-210.
17. Dowell N.G., Cooper E.A., Tibble J., Voon V., Critchley H.D., Cercignani M., Harrison N.A. Acute changes in striatal microstructure predict the development of interferon-alpha induced fatigue. Biol. Psychiatry 2016, 79:320-328.
18. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
19. Ebert D., Feistel H., Loew T., Pirner A. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 1996, 126:91-94.
20. Eisenberger N.I., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. NeuroImage 2009, 47:881-890.
21. Eisenberger N.I., Berkman E.T., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry 2010, 68:748-754.
22. Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front. Neuroendocrinol. 2012, 33:315-327.
23. Felger J.C., Mun J., Kimmel H.L., Nye J.A., Drake D.F., Hernandez C.R., Freeman A.A., Rye D.B., Goodman M.M., Howell L.L., Miller A.H. Chronic interferon-alpha decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology 2013, 38:2179-2187.
24. Felger J.C., Hernandez C.R., Miller A.H. Levodopa reverses cytokine-induced reductions in striatal dopamine release. Int. J. Neuropsychopharmacol. 2015, 18.
25. Felger J.C., Li Z., Haroon E. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry 2015.
26. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., Kelley K.W., Dantzer R., Castanon N. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
27. Galimberti D., Fenoglio C., Lovati C., Venturelli E., Guidi I., Corra B., Scalabrini D., Clerici F., Mariani C., Bresolin N., Scarpini E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 2006, 27:1763-1768.
28. Goldsmith D.R., Rapaport M.H., Miller B.J. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 2016.
29. Grubbs F. Procedures for Detecting Outlying Observations in Samples. Technometrics 1969, 1-21.
30. Harden L.M., du Plessis I., Poole S., Laburn H.P. Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior. Physiol. Behav. 2006, 89:146-155.
31. Haroon E., Woolwine B.J., Chen X., Pace T.W., Parekh S., Spivey J.R., Hu X.P., Miller A.H. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 2014, 39:1777-1785.
32. Haroon E., Felger J.C., Woolwine B.J., Chen X., Parekh S., Spivey J.R., Hu X.P., Miller A.H. Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: preliminary findings. Brain Behav. Immun. 2015, 46:17-22.
33. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66:407-414.
34. Heaton R.K., Miller S.W., Taylor M.J., Grant I. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults 2004, Psychological Assessment Resources, Lutz, FL.
35. Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat. Med. 1990, 9:811-818.
36. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6:65-70.
37. Iverson G.L., Brooks B.L., Ashton Rennison V.L. Minimal gender differences on the CNS vital signs computerized neurocognitive battery. Appl. Neuropsychol. Adult 2014, 21:36-42.
38. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., Bauer J., Lieb K. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000, 152:383-389.
39. Krogh J., Benros M.E., Jorgensen M.B., Vesterager L., Elfving B., Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav. Immun. 2014, 35:70-76.
40. Krzyszton C.P., Sparkman N.L., Grant R.W., Buchanan J.B., Broussard S.R., Woods J., Johnson R.W. Exacerbated fatigue and motor deficits in interleukin-10-deficient mice after peripheral immune stimulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R1109-R1114.
41. Lenczowski M.J., Bluthe R.M., Roth J., Rees G.S., Rushforth D.A., van Dam A.M., Tilders F.J., Dantzer R., Rothwell N.J., Luheshi G.N. Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats. Am. J. Physiol. 1999, 276:R652-R658.
42. Mack W.J., Ducruet A.F., Hickman Z.L., Zurica J., Starke R.M., Garrett M.C., Komotar R.J., Quest D.O., Solomon R.A., Heyer E.J., Sander Connolly E. Elevation of monocyte chemoattractant protein-1 in patients experiencing neurocognitive decline following carotid endarterectomy. Acta Neurochir. 2008, 150:779-784. (discussion 784).
43. Majer M., Welberg L.A., Capuron L., Pagnoni G., Raison C.L., Miller A.H. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav. Immun. 2008, 22:870-880.
44. Martinez-Cengotitabengoa M., Mac-Dowell K.S., Leza J.C., Mico J.A., Fernandez M., Echevarria E., Sanjuan J., Elorza J., Gonzalez-Pinto A. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr. Res. 2012, 137:66-72.
45. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., Martinot J. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am. J. Psychiatry 2001, 158:314-316.
46. Miller A.H., Raison C.L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2015, 16:22-34.
47. Moieni M., Irwin M.R., Jevtic I., Olmstead R., Breen E.C., Eisenberger N.I. Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology 2015, 40:1709-1716.
48. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
49. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 2001, 158:1252-1257.
50. Palta P., Xue Q.L., Deal J.A., Fried L.P., Walston J.D., Carlson M.C. Interleukin-6 and C-reactive protein levels and 9-year cognitive decline in community-dwelling older women: The Women's Health and Aging Study II. J. Gerontol. A Biol. Sci. Med. Sci. 2015, 70:873-878.
51. Pang Y., Fan L.W., Zheng B., Cai Z., Rhodes P.G. Role of interleukin-6 in lipopolysaccharide-induced brain injury and behavioral dysfunction in neonatal rats. Neuroscience 2006, 141:745-755.
52. Piletz J.E., Halaris A., Iqbal O., Hoppensteadt D., Fareed J., Zhu H., Sinacore J., Devane C.L. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J. Biol. Psychiatry 2009, 10:313-323.
53. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
54. Raison C.L., Rye D.B., Woolwine B.J., Vogt G.J., Bautista B.M., Spivey J.R., Miller A.H. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol. Psychiatry 2010, 68:942-949.
55. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
56. Ravnkilde B., Videbech P., Clemmensen K., Egander A., Rasmussen N.A., Rosenberg R. Cognitive deficits in major depression. Scand. J. Psychol. 2002, 43:239-251.
57. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58:445-452.
58. Russo S.J., Nestler E.J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 2013, 14:609-625.
59. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med. 1997, 27:1247-1256.
60. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., Nierenberg A.A., Fava M., Wong K.K. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur. Neuropsychopharmacol. 2008, 18:230-233.
61. Smets E.M., Garssen B., Bonke B., De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995, 39:315-325.
62. Sobin C., Sackeim H.A. Psychomotor symptoms of depression. Am. J. Psychiatry 1997, 154:4-17.
63. Starkstein S.E., Brandt J., Folstein S., Strauss M., Berthier M.L., Pearlson G.D., Wong D., McDonnell A., Folstein M. Neuropsychological and neuroradiological correlates in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:1259-1263.
64. Sutcigil L., Oktenli C., Musabak U., Bozkurt A., Cansever A., Uzun O., Sanisoglu S.Y., Yesilova Z., Ozmenler N., Ozsahin A., Sengul A. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin. Dev. Immunol. 2007, 2007:76396.
65. Taylor B.P., Bruder G.E., Stewart J.W., McGrath P.J., Halperin J., Ehrlichman H., Quitkin F.M. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am. J. Psychiatry 2006, 163:73-78.
66. Taylor M.J., Godlewska B., Near J., Christmas D., Potokar J., Collier J., Klenerman P., Barnes E., Cowen P.J. Effect of interferon-alpha on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. Psychol. Med. 2014, 44:789-795.
67. Torres-Platas S.G., Cruceanu C., Chen G.G., Turecki G., Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav. Immun. 2014, 42:50-59.
68. Westin K., Buchhave P., Nielsen H., Minthon L., Janciauskiene S., Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS ONE 2012, 7.
69. Whale R., Fialho R., Rolt M., Eccles J., Pereira M., Keller M., File A., Haq I., Tibble J. Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort. J. Psychosom. Res. 2015, 79:640-645.
70. Wisdom N.M., Mignogna J., Collins R.L. Variability in Wechsler Adult Intelligence Scale-IV subtest performance across age. Arch. Clin. Neuropsychol. 2012, 27:389-397.
71. Yeudall L.T., Reddon J.R., Gill D.M., Stefanyk W.O. Normative data for the Halstead-Reitan neuropsychological tests stratified by age and sex. J. Clin. Psychol. 1987, 43:346-367.
72. Yirmiya R., Pollak Y., Morag M., Reichenberg A., Barak O., Avitsur R., Shavit Y., Ovadia H., Weidenfeld J., Morag A., Newman M.E., Pollmacher T. Illness, cytokines, and depression. Ann. N. Y. Acad. Sci. 2000, 917:478-487.
73. Yuan L., Liu A., Qiao L., Sheng B., Xu M., Li W., Chen D. The relationship of CSF and plasma cytokine levels in HIV infected patients with neurocognitive impairment. BioMed Res. Int. 2015, 2015:506872.
74. Zunszain P.A., Hepgul N., Pariante C.M. Inflammation and depression. Curr. Top. Behav. Neurosci. 2013, 14:135-151.